Efficacy of Nanocurcumin as an Add-On Treatment for Patients Hospitalized with COVID-19: A Double-Blind, Randomized Clinical Trial

Table 2

The effect of nanocurcumin on the symptoms and clinical features of patients hospitalized with COVID-19.

Variables	Control			Treatment			value (day 0)	value (discharge)
	Day 0	Day of discharge	value	Day 0	Day of discharge	value
Cough	35 (89.7%)	16 (41%)	<0.001	27 (93.1%)	5 (17.2%)	<0.001	0.629	0.036
Sore throat	12 (30.8%)	2 (5.1%)	0.002	12 (41.4%)	0	—	0.365	0.216
Nausea	6 (15.4%)	0	—	5 (17.2%)	1 (%3.4)	0.21	0.837	0.243
Fatigue	30 (76.9%)	26 (66.7%)	0.289	22 (75.9%)	7 (24.1%)	<0.001	0.919	0.0001
Myalgia	20 (51.3%)	6 (15.4%)	0.001	14 (48.3%)	0	—	0.806	0.027
Diarrhea	1 (2.6%)	1 (2.6%)	1	3 (10.3%)	0	—	0.177	0.379
Anorexia	26 (66.7%)	3 (7.7%)	<0.001	16 (55.2%)	2 (6.9%)	<0.001	0.335	0.901
Chills	15 (38.5%)	1 (2.6%)	<0.001	8 (27.6%)	1 (3.4%)	0.039	0.349	0.831
Chest pain	22 (56.4%)	8 (20.5%)	<0.001	18 (62.1%)	3 (10.3%)	0.001	0.639	0.26
Anosmia	21 (53.8%)	21 (53.8%)	1.00	19 (65.6%)	17 (58.6%)	0.62	0.333	0.695
Ageusia	18 (46.2%)	12 (30.8%)	0.031	16 (55.2%)	8 (27.6%)	0.021	0.462	0.776
Oxygen demand	33 (84.6%)	16 (41%)	<0.001	23 (79.3%)	5 (17.2%)	<0.001	0.57	0.036
Oxygen mask (hrs)	19.24 ± 6.8	3.3 ± 8.8	<0.001	15.93 ± 8.8	0	<0.001	0.63	0.053
Respiratory rate	21.2 ± 1.51	21.23 ± 1.6	0.809	20.5 ± 1.12	20 ± 0.617	0.012	0.187	<0.001
Oxygen saturation	89.84 ± 3.4	90.93 ± 3.26	0.002	89.93 ± 2.91	93.25 ± 2.5	<0.001	0.89	0.006
Weight	79.91 ± 16.2	79.81 ± 16.7	<0.001	79.43 ± 16.6	78.83 ± 16.6	<0.001	0.88	0.84

McNemar test; Pearson’s chi-squared test; Wilcoxon signed-rank test; Mann–Whitney test.